Homepage Top Section2

This recommendation will aid in the potential authorisation of the vaccine for use in individuals aged six months and older to prevent Covid-19 in the upcoming 2024-2025 autumn/winter

With the MHRA approval, the updated vaccine will be included in the National Health Service (NHS) autumn vaccination programme. The company noted that the vaccine will be given

The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) [NVX-CoV2705] is now authorised for active immunisation against Covid-19. Following the EUA, the vaccine is also recommended by the US Centers

The application is supported by findings from the Phase III Vivacity-MG3 clinical trial. Assessing the improvement in the MG-ADL score from baseline over 24 weeks was the primary

lncRNAs are a class of therapeutic targets that play a critical role in disease by recruiting RNA-binding proteins (RBPs). The companies will focus on advancing two oncology programmes

A fully human monoclonal antibody, Libtayo acts on the immune checkpoint receptor PD-1 on T cells. It is said to be the first-line monotherapy approved for advanced non-small

This designation is set to provide opaganib with seven years of marketing exclusivity upon approval for this indication. Orphan drug status may also offer additional benefits, including potential

This follows a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) and is valid across all 27 EU member states,

RAG-18 is claimed to be the first saRNA therapeutic to receive ODD status. DMD and BMD  are caused by mutations in the DMD gene. The FDA grants ODD